re: Proposed settlement of infringement litigation with Teva Pharmaceuticals involving sharing of the exclusivity period for the drug Paraplatin.
Main Menu
- About the FTC
- What We Do
- Our History
- Commissioners
- Bureaus & Offices
- Bureau of Competition
- Bureau of Consumer Protection
- Bureau of Economics
- Office of Congressional Relations
- Office of Equal Employment Opportunity and Workplace Inclusion
- Office of International Affairs
- Office of the Executive Director
- Office of the General Counsel
- Office of Policy Planning
- Office of Administrative Law Judges
- Office of Public Affairs
- Office of the Chief Privacy Officer
- Office of the Secretary
- Regional Offices
- Biographies
- Budgets
- Performance
- Office of Inspector General
- The Inspector General
- Reporting Fraud, Waste, Abuse or Mismanagement
- Whistleblower Protection
- FTC Imposter Scams
- Reports and Correspondence
- Semiannual Reports to Congress
- Peer Reviews
- What You Need to Know About the Office of the Inspector General
- CIGIE Presidential Transition Handbook
- Oversight.gov
- Contact the OIG
- FOIA
- Careers at the FTC
- News & Events
- Enforcement
- Policy
- Tips & Advice
- I Would Like To...
